At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Ecopipamdrug
Likely dose
Ecopipam 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ecopipam Treatment of Tourette Syndrome
In Brief
A Phase 2 clinical trial evaluating Ecopipam for Tourette's Syndrome. Completed, enrolled 18 participants across 4 sites.
Detailed Summary
Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette's Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionJul 2012
Study CompletionJul 2013
TodayJul 2026
First PostedNov 19, 2010
Enrollment StartOct 1, 2010
Primary CompletionJul 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.6 years ago
Interventions
Ecopipamdrug
50 or 100 mg tablets given once per day for eight weeks